Based on ratings from 0 stock analysts, the Evaxion Biotech A/S stock price is expected to increase by 348.35% in 12 months. This is calculated by using the average 12-month stock price forecast for Evaxion Biotech A/S. The lowest target is $7 and the highest is $18. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedEVAX 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Evaxion Biotech A/S to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on EVAX. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of EVAX.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Swayampakula Ramakanth HC Wainwright & Co. | Buy | $14 | Reiterates | Nov 1, 2024 |
Swayampakula Ramakanth HC Wainwright & Co. | Buy | $14 | Reiterates | Sep 26, 2024 |
Swayampakula Ramakanth HC Wainwright & Co. | Buy | $14 | Reiterates | Sep 20, 2024 |
Swayampakula Ramakanth HC Wainwright & Co. | Buy | $14 | Reiterates | Aug 16, 2024 |
Swayampakula Ramakanth HC Wainwright & Co. | Buy | $14 | Reiterates | Aug 1, 2024 |
Swayampakula Ramakanth HC Wainwright & Co. | Buy | $14 | Reiterates | Jun 4, 2024 |
Swayampakula Ramakanth HC Wainwright & Co. | Buy | $14 | Reiterates | Apr 3, 2024 |
Ahu Demir Ladenburg Thalmann | Buy | $8 | Upgrade | Apr 2, 2024 |
Swayampakula Ramakanth HC Wainwright & Co. | Buy | $14 | Reiterates | Mar 20, 2024 |
Swayampakula Ramakanth HC Wainwright & Co. | Buy | $14 | Initiates | Feb 12, 2024 |
Ahu Demir Ladenburg Thalmann | Neutral | Downgrade | Dec 21, 2023 | |
Thomas Flaten Lake Street | Buy | $7 | Maintains | Mar 31, 2023 |
Jeff Jones Oppenheimer | Outperform | $11 | Maintains | Nov 17, 2022 |
Jeff Jones Oppenheimer | Outperform | $16 | Assumes | Jul 18, 2022 |
Kevin DeGeeter Oppenheimer | Outperform | $18 | Initiates | Mar 2, 2021 |
When did it IPO
2020
Staff Count
49
Country
Denmark
Sector/Industry
Healthcare/Biotechnology
CEO
Market Cap
$13.3M
In 2023, EVAX generated $73,000 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that EVAX's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Evaxion Biotech (NASDAQ: EVAX) reported positive preclinical data for its CMV vaccine EVX-V1, to be presented at the 9th International Conference on Vaccines Research & Development in Boston.
Why It Matters - Positive preclinical data for Evaxion's CMV vaccine can boost investor confidence, potentially increasing stock value and signaling progress in the biotech sector.
Summary - Evaxion Biotech A/S (NASDAQ: EVAX) announced its Q3 2024 financial results and provided a business update on its AI-Immunologyโข powered vaccine developments.
Why It Matters - Evaxion's update and Q3 financial results signal its progress in AI-driven vaccine development, impacting investor confidence and potential future valuation.
Summary - Evaxion Biotech A/S (NASDAQ: EVAX) will release its third quarter 2024 financial results and business update on October 31, 2024, before market opening.
Why It Matters - Evaxion's upcoming Q3 financial results and business update could impact its stock price, reflecting performance and strategic direction in the AI-vaccine sector.
Summary - Evaxion Biotech (NASDAQ: EVAX) reported validation of its AI-Immunologyโข vaccine target predictions from three clinical trials, enhancing its position in the biotech sector.
Why It Matters - Successful validation of AI-driven vaccine targets enhances Evaxion's credibility, potentially leading to increased investor confidence and market interest in its innovative technology and future products.
Summary - Evaxion Biotech A/S (NASDAQ: EVAX) is advancing its AI-Immunologyโข platform, focusing on clinical evidence to enhance its vaccine development.
Why It Matters - Evaxion's advancements in its AI-Immunologyโข platform could enhance vaccine efficacy, driving potential market growth and investor interest in its future clinical successes.
Summary - Evaxion Biotech A/S has signed an option and license agreement with Merck for two preclinical vaccine candidates, enhancing their collaboration and adding significant value to Evaxion.
Why It Matters - The agreement with Merck enhances Evaxion's pipeline and potential revenue, signaling confidence in its AI-driven vaccine technology, which may attract investor interest and boost stock performance.